🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 98401F105
- Market Cap
- Large Cap
- IPO
- 12/2/2013 · $5.50/share
Business: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.
Company Contact
- CEO
- Bassil I. Dahiyat, Ph.D.
- CFO
- Bart Cornelissen
- Headquarters
- 465 North Halstead Street, Suite 200, Pasadena, CA 91107
- Phone
- 626-305-5900
- Fax
- 626-305-0350
- Investor Relations
- Charles Liles · 626-737-8118 · cliles@xencor.com